GlassScriptPhysician profile
Wiggin Wu Lee
NPI 1811239064
$2,660.10
in general payments reported to CMS, 2019-2025
20 companies · $973 in 2025
The $973 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $53.00 · 2021: $26.50 · 2023: $174 · 2024: $1,002 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.15 |
| Education | $192.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $893.57 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $321.72 | 2023-2024 | Vtama |
| Pfizer INC. | $292.49 | 2019-2025 | |
| Dermira, INC. | $152.34 | 2019 | |
| Incyte Corporation | $143.79 | 2024-2025 | Opzelura |
| Organon LLC | $108.02 | 2025 | Vtama |
| Genzyme Corporation | $106.58 | 2024-2025 | |
| Allergan, INC. | $97.33 | 2019 | |
| Amgen INC. | $80.22 | 2024-2025 | Otezla |
| Vyne Pharmaceuticals INC. | $79.50 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $67.78 | 2019 | |
| Arcutis Biotherapeutics, INC. | $58.63 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $52.04 | 2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $48.17 | 2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $46.66 | 2024-2025 | Dupixent, Libtayo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.12 | 2024 | |
| Celgene Corporation | $24.87 | 2019 | |
| Convatec INC. | $23.72 | 2025 | |
| Galderma Laboratories, L.P. | $18.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wiggin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.